EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis

Ying Wu, Lifeng Kong, Ejakpovi Emmanuel Oghenefejiro, Xuan Cao, Deqian Wang, Chenmeng Tao, Xiangyang Wang, Rong Qin, Yao Ji, Liang Yin

Breast Cancer Research and Treatment · 2026-11 · 220 (1)

DOI: 10.1007/s10549-026-08099-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 14.11.2026. Verfasst von Ying Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carboplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Carboplatin improves pathological complete response (pCR) in triple-negative breast cancer (TNBC), but its effect on long-term survival remains uncertain. We conducted a strict randomized-contrast meta-analysis to assess the incremental effect of adding carboplatin to otherwise substantially comparable chemotherapy regimens.

Methods

PubMed, Embase, and Cochrane CENTRAL were searched from database inception. Phase II/III randomized controlled trials comparing carboplatin-containing versus carboplatin-free otherwise substantially comparable chemotherapy regimens in non-metastatic TNBC were included. Directly reported HRs for trial-defined disease-control endpoints and OS, and odds ratios (ORs) for pCR were pooled using random-effects models. Sensitivity analyses assessed the robustness of the disease-control and OS findings.

Results

Seven randomized contrasts (2,627 randomized participants) contributed disease-control evidence. Carboplatin significantly improved trial-defined disease control (HR 0.779, 95% CI 0.671–0.904; p = 0.001; I^2 = 40.6%) and increased pCR rates (OR 2.038, 95% CI 1.653–2.512; p < 0.001; I^2 = 29.9%). The OS estimate favored carboplatin but was compatible with no effect (HR 0.810, 95% CI 0.627–1.046; p = 0.107; I^2 = 41.4%). The sensitivity analysis restricted to aligned EFS-type endpoints remained favorable (HR 0.793, 95% CI 0.656–0.960; p = 0.017; I^2 = 31.4%).

Conclusion

Carboplatin addition significantly improves pCR and trial-defined disease control in TNBC when evaluated in otherwise substantially comparable randomized chemotherapy contrasts. However, the strict evidence did not establish an OS benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarboplatinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAnthracyclinesTaxoidsPathologic Complete ResponseTreatment OutcomeBridged-Ring CompoundsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Adjuvant chemotherapyCarboplatinMeta-analysisNeoadjuvant chemotherapyTriple-negative breast cancer

Substanzen

CarboplatinAnthracyclinesTaxoidstaxaneBridged-Ring Compounds

Autor:innen und Institutionen

  • Department of Breast Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
  • School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
  • Department of Ultrasound, Taizhou Central Hospital (Affiliated Hospital of Taizhou University), Taizhou, Zhejiang, China.
  • Department of Traditional Chinese Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
  • Department of Medical Oncology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
  • Department of Breast and Thyroid Surgery, The Fourth Division Hospital of Xinjiang Production and Construction Corps, Affiliated Hospital of Shihezi University School of Medicine, Shihezi, Xinjiang, China. 110041112@qq.…

Zitieren

APA

Wu, Y., Kong, L., Oghenefejiro, E. E., Cao, X., Wang, D., Tao, C., Wang, X., Qin, R., Ji, Y., & Yin, L. (2026). Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis. Breast Cancer Research and Treatment, 220(1). https://doi.org/10.1007/s10549-026-08099-w

Vancouver

Wu Y, Kong L, Oghenefejiro EE, Cao X, Wang D, Tao C, et al. Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis. Breast Cancer Research and Treatment. 2026;220(1). doi:10.1007/s10549-026-08099-w

BibTeX
@article{Wu2026,
  author = {Wu, Ying and Kong, Lifeng and Oghenefejiro, Ejakpovi Emmanuel and Cao, Xuan and Wang, Deqian and Tao, Chenmeng and Wang, Xiangyang and Qin, Rong and Ji, Yao and Yin, Liang},
  title = {Survival benefit of adding carboplatin to standard anthracycline–taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1007/s10549-026-08099-w}
}
Kostenlos starten →